YUTREPIA is an inhaled treprostinil dry powder that is indicated to improve exercise ability in patients with PAH (WHO Group 1) or in patients with PH-ILD (WHO Group 3). The active ingredient in YUTREPIA, treprostinil, is well studied and proven to be safe and effective.
YUTREPIA is made using a novel technology that produces drug particles that have the same size and shape and are free-flowing, so they may get deep into the lungs.
In contrast to conventional dry powders, delivery of YUTREPIA powder does not depend on strong inhalation by patients to break up and disperse medication.
WHO = World Health Organization
YUTREPIA consists of a small, pocket-sized inhaler and replaceable drug capsules.
No refrigeration is needed—YUTREPIA is stored at room temperature.
The inhaler does not need to be prepared and used in a specific position, reducing the chance of making an error or spilling the drug.
The easy-to-use, low-effort inhaler has been trusted by doctors and people with lung conditions for decades.
PATIENTS NEW TO PROSTACYCLIN COULD WALK FARTHER
Timed walking distance improved as dose increased through 24 months.
PATIENTS TRANSITIONING FROM TYVASO® NEBULIZER COULD WALK FARTHER
After 2 months, timed walking distance improved by 19 meters—and improvements lasted through 1 year.**
*In the clinical study for PAH, patients were also receiving up to 2 non-prostacyclin oral therapies as part of their overall treatment.
**At the start of the study the average distance walked in 6 minutes was 401 meters.
100%
of patients in a clinical study who switched from the TYVASO® nebulizer preferred the YUTREPIA device when asked after 4 months of use.*
TYVASO® is a registered trademark of United Therapeutics Corporation.
*Data from the INSPIRE clinical trial: 49 out of 49 participants preferred the YUTREPIA device over the TYVASO nebulizer—40 participants strongly preferred the YUTREPIA device, and 9 preferred it.
The most common side effects are:
This safety profile is consistent with that reported for inhaled treprostinil solution in clinical studies of PAH patients.
These are not all the possible side effects of YUTREPIA. Be sure to tell your healthcare team about any side effect that bothers you. Continue to take YUTREPIA as prescribed unless you are told to stop by your healthcare team.
Call your doctor for medical advice about side effects or if you have trouble breathing.
Talk to your healthcare team about how to manage any side effects.
Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.
Especially tell your healthcare provider if you take:
The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
YUTREPIA is a prescription medicine used in adults to treat:
The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1-888-393-5732.
Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.
Especially tell your healthcare provider if you take:
What are the possible side effects of YUTREPIA?
This product can cause serious side effects, including:
The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1-888-393-5732.